Peijia Medical (HKG:9996) completed the first patient treatment of the first-in-man clinical trial of ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system on April 2, an April 6 filing with the Hong Kong bourse said.
The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, during which the system was used to implant a TaurusElite(r) transcatheter aortic valve in a patient with severe aortic stenosis.
ReachTactile, the medical device manufacturer's internally developed robotic-assisted TAVR system, offers an innovative solution for TAVR therapy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。